Notch Inhibition via GSI Treatment Elevates Protein Synthesis in C2C12 Myotubes

• Main Authors: Joshua R. Huot, Joseph S. Marino, Michael J. Turner, Susan T. Arthur
• Format: Article
• Language: English
• Published: MDPI AG 2020-06-01
• Series: Biology
• Subjects: protein synthesis; GSI; notch; hypertrophy
• Online Access: https://www.mdpi.com/2079-7737/9/6/115

The role of Notch signaling is widely studied in skeletal muscle regeneration but little is known about its influences on muscle protein synthesis (MPS). The purpose of this study was to investigate whether Notch signaling is involved in the regulation of MPS. C2C12 cells were treated with a γ-secretase inhibitor (GSI), to determine the effect of reduced Notch signaling on MPS and anabolic signaling markers. GSI treatment increased myotube hypertrophy by increasing myonuclear accretion (nuclei/myotube: <i>p </i>= 0.01) and myonuclear domain (myotube area per fusing nuclei: <i>p </i>< 0.001) in differentiating C2C12 cells. GSI treatment also elevated myotube hypertrophy in differentiated C2C12s (area/myotube; <i>p </i>= 0.01). In concert, GSI treatment augmented pmTOR Ser2448 (<i>p </i>= 0.01) and protein synthesis (using SUnSET method) in myotubes (<i>p </i>< 0.001). Examining protein expression upstream of mTOR revealed reductions in PTEN (<i>p </i>= 0.04), with subsequent elevations in pAKT Thr308 (<i>p </i>< 0.001) and pAKT Ser473 (<i>p </i>= 0.05). These findings reveal that GSI treatment elevates myotube hypertrophy through both augmentation of fusion and MPS. This study sheds light on the potential multifaceted roles of Notch within skeletal muscle. Furthermore, we have demonstrated that Notch may modulate the PTEN/AKT/mTOR pathway.